Healius LimitedASX: HLS

FY26 trading update and strategic review of assets

· Issued by Healius Limited

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Healius Limited has announced a trading update for the fiscal year, including a strategic review of its assets, particularly Agilex Biolabs. The company expects underlying earnings before tax and depreciation to fall within a specified range. Pathology volumes and revenue have shown mixed results, with a slight decline in volumes but an increase in revenue for the year to date. Healius is exploring a potential sale of Agilex Biolabs following unsolicited approaches, which will not affect its core Pathology operations.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Healius Limited on 6ix

Earlier from Healius

Later from Healius

All Healius news releases